Cargando…

Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate

INTRODUCTION: In patients with axial spondyloarthritis (axSpA), biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended to those with inadequate response or contraindications to non-steroidal anti-inflammatory drugs (NSAIDs). In case of failure of the first bDMARD, a switch withi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poddubnyy, Denis, Hammel, Ludwig, Heyne, Marvin, Veit, Justyna, Jentzsch, Claudia, Baraliakos, Xenofon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Rheumatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7528363/ https://www.ncbi.nlm.nih.gov/pubmed/32998926 http://dx.doi.org/10.1136/bmjopen-2020-039059

Ejemplares similares

Secukinumab in axial spondyloarthritis: a narrative review of clinical evidence
por: Braun, Jürgen, et al.
Publicado: (2021)

Clinical characteristics of importance to outcome in patients with axial spondyloarthritis: protocol for a prospective descriptive and exploratory cohort study
por: Andreasen, Rikke Asmussen, et al.
Publicado: (2017)

Old and new treatment targets in axial spondyloarthritis
por: Rios Rodriguez, Valeria, et al.
Publicado: (2015)

Analysis of HLA-B15 and HLA-B27 in spondyloarthritis with peripheral and axial clinical patterns
por: Londono, John, et al.
Publicado: (2015)

(Un)Spoken realities of living with axial spondyloarthritis: a qualitative study focused on couple experiences
por: Raybone, Kerry, et al.
Publicado: (2019)

Characteristics of Late-Onset Spondyloarthritis: Data from the Moroccan Registry of Biological Therapies in Rheumatic Diseases
por: Mougui, Ahmed, et al.
Publicado: (2023)

Qualitative interview study exploring the patient experience of living with axial spondyloarthritis and fatigue: difficult, demanding and draining
por: Pearson, Nathan Ashley, et al.
Publicado: (2022)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Efficacy of tofacitinib in reduction of inflammation detected on MRI in patients with Psoriatic ArthritiS presenTing with axial involvement (PASTOR): protocol of a randomised, double-blind, placebo-controlled, multicentre trial
por: Proft, Fabian, et al.
Publicado: (2021)

The Role of Imaging in Diagnosing Axial Spondyloarthritis
por: Khmelinskii, Nikita, et al.
Publicado: (2018)

Management of Axial Spondyloarthritis – Insights into Upadacitinib
por: Braun, Jürgen, et al.
Publicado: (2022)

JAK Inhibitors for the Treatment of Axial Spondyloarthritis
por: Klavdianou, Kalliopi, et al.
Publicado: (2023)

Association of anxiety, depression and resilience with overall health and functioning in axial spondyloarthritis (axSpA): a cross-sectional study
por: Chung, Deborah Xin Yi, et al.
Publicado: (2023)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

A glance into the future of diagnosis and treatment of spondyloarthritis
por: Navarro-Compán, Victoria, et al.
Publicado: (2022)

Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain
por: Benavent, Diego, et al.
Publicado: (2022)

GlutenSpA trial: protocol for a randomised double-blind placebo-controlled trial of the impact of a gluten-free diet on quality of life in patients with axial spondyloarthritis
por: Couderc, Marion, et al.
Publicado: (2020)

Study protocol: Comparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of Structural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) – an open-label randomized controlled multicenter trial
por: Proft, Fabian, et al.
Publicado: (2017)

Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis
por: Gentileschi, Stefano, et al.
Publicado: (2020)

The impact of gender and sex on diagnosis, treatment outcomes and health-related quality of life in patients with axial spondyloarthritis
por: Marzo-Ortega, Helena, et al.
Publicado: (2022)

Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis
por: Kahn, Maria, et al.
Publicado: (2023)

Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
por: Uhrenholt, Line, et al.
Publicado: (2019)

Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain
por: Schweikert, Bernd, et al.
Publicado: (2020)

Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis
por: Poddubnyy, Denis
Publicado: (2020)

Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum
por: Sivera, Francisca, et al.
Publicado: (2023)

Treatment of Axial Spondyloarthritis: What Does the Future Hold?
por: Poddubnyy, Denis, et al.
Publicado: (2020)

Efficacy and safety of secukinumab in patients with spondyloarthritis and enthesitis at the Achilles tendon: results from a phase 3b trial
por: Behrens, Frank, et al.
Publicado: (2021)

Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo‐Controlled Phase III Study
por: Deodhar, Atul, et al.
Publicado: (2020)

What is the optimal target for a T2T approach in axial spondyloarthritis?
por: Sieper, Joachim, et al.
Publicado: (2021)

Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT
por: Braun, Jürgen, et al.
Publicado: (2021)

Rapid improvement in spinal pain in patients with axial spondyloarthritis treated with secukinumab: primary results from a randomized controlled phase-IIIb trial
por: Poddubnyy, Denis, et al.
Publicado: (2021)

AScall – Automatic Allele-Specific qPCR Analysis
por: Blagodatskikh, Konstantin, et al.
Publicado: (2020)

Impact of Rheumatic Diseases on Oral Health-Related Quality of Life
por: Aloyouny, Ashwag Y, et al.
Publicado: (2022)

Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis
por: Braun, Juergen, et al.
Publicado: (2023)

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
por: Braun, Jürgen, et al.
Publicado: (2019)

Identifying parameters associated with delayed diagnosis in axial spondyloarthritis: data from the European map of axial spondyloarthritis
por: Garrido-Cumbrera, Marco, et al.
Publicado: (2021)

The Efficacy and Safety of Subcutaneous Ixekizumab for the Treatment of Axial Spondylarthritis: A Systematic Review and Meta-Analysis
por: Alzahrani, Ziyad, et al.
Publicado: (2023)

Patient‐Reported Impact of Axial Spondyloarthritis on Working Life: Results From the European Map of Axial Spondyloarthritis Survey
por: Garrido‐Cumbrera, Marco, et al.
Publicado: (2021)

Patient and parent perspectives on transition from paediatric to adult healthcare in rheumatic diseases: an interview study
por: Jiang, Ivy, et al.
Publicado: (2021)

Effectiveness and cost-effectiveness of combined asynchronous telemonitoring and patient-initiated care for spondyloarthritis: protocol for a pragmatic multicentre randomised controlled trial (TeleSpA Study)
por: Hermans, Kasper, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3frdn6638vaon26pvs840ie4i8